Vectura's GSK royalties agreements firing on all cylinders

Alexander Bueso Sharecast | 16 Feb, 2017 07:27 | | |

vectura fox
  • 154.10
  • -1.09%-1.70
  • Max: 157.50
  • Min: 148.00
  • Volume: 2,744,808
  • MM 200 : n/a
17:17 30/03/17
  • 3,471.04
  • -0.04%-1.41
  • Max: 3,476.96
  • Min: 3,459.98
  • Volume: 0
  • MM 200 : n/a
17:18 30/03/17
  • 19,011.93
  • 0.18%33.28
  • Max: 19,016.28
  • Min: 18,950.65
  • Volume: 0
  • MM 200 : n/a
17:30 30/03/17
  • 14,415.90
  • -0.38%-54.34
  • Max: 14,534.88
  • Min: 14,397.55
  • Volume: 0
  • MM 200 : n/a
17:30 30/03/17
  • 4,069.44
  • -0.02%-0.74
  • Max: 4,075.98
  • Min: 4,053.80
  • Volume: 0
  • MM 200 : n/a
17:30 30/03/17
  • 4,011.01
  • -0.02%-0.79
  • Max: 4,017.26
  • Min: 3,996.06
  • Volume: 0
  • MM 200 : n/a
17:18 30/03/17
  • 4,469.52
  • 0.14%6.05
  • Max: 4,474.39
  • Min: 4,455.27
  • Volume: 0
  • MM 200 : n/a
17:18 30/03/17

Vectura Group hit its royalty cap on sales of GlaxoSmithKline´s Ellipta range of products in 2016, one year ahead of forecasts.

The cap was equivalent to £9.0m.

The inhaled airways disease-focused business was also set to record £5.4m of 2016 revenues under a separate single digit percentage royalty agreement with GSK on its Ellipta products.

That latter royalties agreement was a legacy arrangement from its merger with Skyepharma.

Vectura would also receive £7.3m of royalties under a separate royalties agreement which GSK decided not to extend in July 2016 and which had also been running ahead of expectations.

James Ward-Lilley, Chief Executive Officer, commented: "We are pleased to see continued momentum in Vectura's recurring revenues driven by the strong performance of our partnered marketed respiratory products. The merger with Skyepharma has added to the Group's growing revenue streams and combined with anticipated pipeline and partnered programme developments, Vectura is well positioned to capture a growing share of the evolving respiratory market."

More news

19:01 Bonds: Gilts continue advance as investors focus on start of Brexit talks

These were the movements in some of the most widely-followed 10-year sovereign bond yields:

18:43 Europe close: Basic Resources, Oil&Gas lead gains

European equity markets added to their first quarter tally, with shares in Basic Resources and Oil&Gas spearheading the advance even as the single European currency came under selling pressure on the back of weaker-than-expected readings on inflation in Germany and Spain and hawkish Fedspeak.

17:15 London close: FTSE's progress dampened by ex-dividends, sterling's rise and Brexit worries

Stocks in London passed through a relatively quiet Thursday, with numerous ex-dividend equities, a stronger sterling and Brexit worries combining to dampen progress heading into the end of the first quarter.

17:11 Sector movers: Industrial engineers, miners jump at quarter-end

Cyclicals were clearly in favour heading into the end of the first quarter, on the back of positive analyst chatter out of some of the top brokers in the world and as prices for most key industrial metals reversed their losses seen in overnight trading.

16:58 FTSE 250 movers: Petra provides the shine; RPC melts

Petra Diamonds shone brightly on the FTSE 250 on Thursday with shares in the company up 9% as it announced a $600m notes issue and refinancing package.

16:39 Friday preview: UK GDP story should remain unchanged

UK national growth figures for the fourth quarter of last year will be the main economic data event on Friday, along with details on the current account and the index of services and house price data from Nationwide.

15:52 Small cap news round-up

Insurance premium finance-focussed finance group Orchard Funding Group announced its unaudited results for the six months to 31 January on Thursday, with the board reporting it lent £31.1m for the period.

15:47 Bank of England could use palm oil in new £20 note

The Bank of England is pondering using palm oil in the production of the new £20 note following criticism from vegans and religious groups after the revamped £5 note was found to contain traces of animal fat.

14:45 Results round-up: International Public Partnerships, Polypipe Group

International Public Partnerships posted its full-year results for the 12 months to 31 December on Thursday, reporting net asset value growth of 24.3% to £1.6bn.

15:44 Broker tips: Morrison, Kingfisher, Ashtead, Admiral

Bank of America Merrill Lynch upgraded Morrison to ‘buy’ from ‘underperform’ and lifted the price target to 275p from 220p.